Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indivior plc

http://indivior.com/

Latest From Indivior plc

After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential

Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.

Business Strategies Launches

Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

Deal Watch Business Strategies

Keeping Track: Immunology Drives US FDA Action, With Approvals For AZ/Amgen’s Tezspire, Argenx’s Vyvgart, And New JAK Uses

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Review

Deal Watch: BMS Licenses Bispecific TCR Candidate From Immatics

BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Indivior Inc.
    • Indivior UK Limited
    • Reckitt Benckiser Pharmaceuticals Inc. (RBP)
UsernamePublicRestriction

Register